Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #1116

    Det var en ny mand som skulle lave overskriften.Jeg får den lavet om. 🙂

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #1117

      Nohope...Lyder jeg som en sur negativ shorter i podcasten. 🙂

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #1118

        Oversigt med links til ProInvestors 22 nye FB-grupper https://www.proinvestor.com/index.php?p=debat_1&postid=93825

        1 Reply Last reply
        0
        • D Offline
          D Offline
          deleted-user
          wrote on sidst redigeret af
          #1119

          Pæn omsætning i luk....

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #1120

            over 150.000 in the auction?

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #1121

              God morgen. 🙂

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #1122

                Asien: Stigninger på baggrund af optimisme og teknisk omlægning https://www.proinvestor.com/investornyt/675481/asien-stigninger-pa-baggrund-af-optimisme-og-teknisk-omlaegning-ny

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #1123

                  Fredagens aviser med SAS, Matas og Novo Nordiskhttps://www.proinvestor.com/investornyt/675476/fredagens-aviser-med-sas-matas-og-novo-nordisk

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #1124

                    STOCKHOLM (Nyhetsbyrån Direkt) Astra Zenecas Tagrisso (osimertinib) har blivit godkänt i EU för behandling av vuxna patienter i tidig fas av så kallad EGFR-muterad icke småcellig lungcancer.

                    Det framgår av ett pressmeddelande.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1125

                      indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer.html

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #1126

                        did we know this: KCR Cap
                        @KcrCap

                        $HALO has patent protection on ENHANZE through 2024 in Europe and 2027 in the US. Royalty rates drop by 50% upon patent expiration, but royalties can still be collected for 10 years following commercial launch https://twitter.com/KcrCap/status/1398041938645995520

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1127

                          Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17565

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #1128

                            this is in Korean, from the Prof who will present on amivantamab at ASCO http://www.dreamdrug.com/Users/News/NewsView.html?ID=276681

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #1129

                              Langtidsoverlevelse forbedret i MM https://haematologisktidsskrift.dk/sygdomme/myeloma/846-langtidsoverlevelse-vokser-voldsomt-for-myelomatosepatienter.html

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #1130

                                Link Preview Image
                                Bispecific antibodies in review: from cell line development to manufacturing

                                With the advent of a technology that targets two different epitopes simultaneously, growth in the global bispecific antibody market has accelerated in recent years. Dr Kevin Robinson spoke to Gregory Bleck, Vice President of Research and Development at Catalent Biologics, to discover more about the pros, cons and applications of these innovative therapies

                                favicon

                                (www.manufacturingchemist.com)

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #1131

                                  BsAbs view from Catalent Biologics:

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #1132

                                    @Sukkeralf was there anything interesting in that Lava presentation?

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #1133

                                      Early days so hard to say - but preclinically I think it looks very promising.

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #1134

                                        I would have loved to hear anything about their partnership with Janssen - but as usual you dont get any insight there

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #1135

                                          ok. something to keep on the radar
                                          😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger